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Abstract In current clinical practice, peripherally inserted
central catheters (PICCs) are typically inserted using external
anatomical measurements and a confirmatory chest X-ray, or
using fluoroscopy. The Sherlock 3CG Tip Confirmation
System (TCS) allows magnetic tracking of the PICC tip
during insertion and confirmation of the final location using
ECG, meaning that most patients will not require a chest
X-ray or fluoroscopy. The Sherlock 3CG TCS was evalu-
ated in 2014 by the UK National Institute for Health and
Care Excellence (NICE) as part of the Medical Technologies
Evaluation Programme. The company (C.R. Bard Ltd)
identified four abstracts, one paper pending publication and
questionnaire data from NHS users of the Sherlock 3CG
TCS. None of the evidence included a comparator arm.
Placement accuracy of PICCs using the Sherlock 3CG TCS
where a chest X-ray was also used ranged from 79.5 to
100 %. The company reported that 9 out of 16 NHS centres
that used the Sherlock 3CG TCS were no longer using chest
X-rays to routinely confirm PICC tip location. The evidence
did not report the need for catheter repositioning, re-inser-
tion, staff time savings, treatment delays, length of stay,
quality of life outcomes or complications. The company’s
model found that the Sherlock 3CG TCS was cost saving
by GBP25.67 per patient compared to blind bedside PICC
insertion. The External Assessment Centre (EAC) adapted
the company’s model to test alternative assumptions for
nurse time, theatre cost, malposition rate and reinsertion
method, and found that the Sherlock 3CG TCS was cost
incurring by GBP9.37 per patient compared to blind bedside
PICC insertion. The use of the Sherlock 3CG TCS in the
UK NHS compared to blind PICC insertion using a confir-
matory chest X-ray appears to hover around being cost
neutral. Staff time and accuracy were key drivers in the
model: evidence for these is sparse and the reality will vary
in different situations. If evidence became available for
outcomes after the initial insertion, such as replacement,
complications and adverse events, the cost implications may
change. The direction of this potential change is not known.
NICE published guidance MTG24 in March 2015 recom-
mending that the case for adoption of Sherlock 3CG TCS
was supported by the evidence.
Key Points for Decision Makers
The Sherlock 3CG TCS has already been
implemented in 16 NHS sites, and routine use of
chest X-rays for confirming PICC tip location has
been eliminated in some of these.
Use of the Sherlock 3CG TCS appears to be
approximately cost neutral compared to blind PICC
insertion, based on the available low quality
evidence. It may be cost saving if there are
reductions in nurse time, X-ray provision, portering
or the number of reinsertions required.
There is some evidence that the Sherlock 3CG TCS
can improve tip positioning accuracy compared to
blind placement of PICCs.
There is no evidence on the effect of Sherlock 3CG
TCS on the time to treatment, length of stay, clinical
outcomes or patient experience.
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1 Introduction
This is part of a series summarising guidance produced by
the National Institute for Health and Care Excellence
(NICE) Medical Technologies Evaluation Programme
(MTEP). The process is explained by Campbell and
Campbell in the first publication of this series [1]. This
article summarises the External Assessment Centre (EAC)
report [2] and Medical Technology Guidance (MTG) for
the Sherlock 3CG Tip Confirmation System (TCS) for
placement of peripherally inserted central catheters [3].
The EAC that produced the assessment report for the
Sherlock 3CG TCS was Cedar, a collaboration between
Cardiff and Vale University Health Board, Cardiff
University and Swansea University.
2 Background
Peripherally inserted central catheters (PICCs) use a
catheter inserted at a peripheral vein using ultrasound
guidance and gently moved through the vein until the tip is
in the superior vena cava or right atrium. The insertion site
is typically the brachial or cephalic vein in the upper arm,
leading to the right subclavian vein [4, 5] (Fig. 1).
PICCs are used in different circumstances, including:
• measuring circulatory or heart functions
• providing long-term access route for infusions and
blood tests
• delivering drugs that require rapid dilution, e.g.
chemotherapy
• delivering contrast medium for cardiac imaging.
The different clinical uses for PICCs mean that there is
variation in the pathways that occur in practice. PICCs may
be inserted in intensive care units (ICUs), in outpatient
clinics, at the bedside, and in fluoroscopy and X-ray
departments. The clinical staff who insert PICCs include
specialist nurses, radiologists and doctors [2].
The two methods for placing PICCs which are currently
standard are [2]:
• Blind placement—the catheter is pushed into the vein a
set distance according to anatomical measurements
taken externally on the patient. Once the PICC is
placed, the correct position is confirmed using a chest
X-ray.
• Fluoroscopy-guided PICC placement—the tip location
can be visualised and the final location confirmed
during the procedure.
In the UK, the preferred position for the PICC tip
position is normally the mid or lower superior vena cava,
cavo-atrial junction, or the high right atrium, based on
European guidelines [4]. There is no international
consensus.
The length of time for which PICCs are in place ranges
from a few days to over a year: 1 week to 3 months is most
typical. During this time, the location of the tip may move
slightly. This would be identified only if it caused a clinical
problem, or if there was an X-ray or imaging for another
reason.
There are instances of gross malpositioning, for example
if the catheter enters the left subclavian vein or the right
internal jugular vein. It may be possible to correct such
malpositioning with the catheter in place. Otherwise, the
PICC is removed and a new PICC inserted. PICC malpo-
sitioning may cause complications such as catheter mal-
function, cardiac arrhythmia or tamponade [5]. More minor
malpositioning has less obvious clinical relevance. The
confirmatory chest X-ray may show that the tip is inserted
slightly too far, and in this case it can be pulled back to
achieve the desired position. Some PICC teams will intend
to always place the tip too far, and pull back by a measured
amount following the chest X-ray. The PICC can never be
moved further in after initial insertion, as the external
section is no longer sterile.
2.1 Sherlock 3CG Tip Confirmation System
The Sherlock 3CG TCS uses a sensor to track a magnetic
tip at the distal end of the catheter and internal ECG
measurements to confirm the position of the catheter tip
relative to the heart. For most patients, a chest X-ray will
not be required to confirm tip placement, and the procedure
can be completed at the patient’s bedside, or in an outpa-
tient clinic.
The Sherlock 3CG TCS sensor is a class I medical
device, which obtained a CE mark in December 2011. The
sensor must be used with the Sherlock 3CG TCS mag-
netic stylet, and Power PICC SOLO catheter—class II
medical devices, which obtained CE marking in February
2012. The Sherlock 3CG TCS cannot be used with other
types of catheter.
2.2 National Institute for Health and Care
Excellence (NICE) scope
NICE defines the scope of the evaluation prior to the
company’s submission of evidence [6].
Population Adult patients undergoing PICC insertion.
Intervention The Sherlock 3CG TCS, used by a
healthcare professional trained in PICC placement. Previ-
ous versions of the system that did not include the use of
both magnetic tracking and ECG tip confirmation were
excluded.
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Comparators There were two comparators, based on
current practice:
• Blind PICC insertion followed by chest X-ray.
• Fluoroscopy.
Outcomes Included accuracy of catheter tip placement,
requirement for confirmatory chest X-ray, catheter mal-
position rates, catheter re-positioning rates, impact of
malposition-related complications, time to treatment, staff
time, length of stay, fluoroscopy needed to place the PICC,
time for PICC insertion, patient experience, patient quality
of life and device-related adverse events.
The benefits to patients claimed by the company are [2,
6, 7]:
• Better accuracy of PICC placement.
• Better outcomes by reducing the incidence of catheter
malposition and post-procedural repositioning.
• Removed the need for a chest X-ray or fluoroscopy to
confirm tip location after PICC insertion.
• Reduced treatment delays due to intra-procedural
verification of tip position.
• Safe method for PICC tip placement with no associated
adverse events or complications.
• PICC placement and tip verification are during the
same procedure.
• It improves patient experience and increases the
patient’s confidence in the PICC placer.
The benefits to the healthcare system claimed by the
company are:
• A reduced and more efficient care pathway because no
chest X-ray is needed.
• Lower staff requirements (radiologists/radiology
nurses/radiographers/radiology healthcare support
workers) because the need for X-ray confirmation is
reduced. Also reduced need for porters for patient
transfer and doctors for X-ray assessment.
• Potential reduction of bed occupancy due to reductions
in treatment delays.
• Reduced costs of consequences of malpositioning.
• Reduced costs of using resource intensive departments
such as radiology.
3 Review of Clinical and Economic Evidence
The company provided an evidence submission to NICE
that summarised the clinical and cost evidence for the
Sherlock 3CG TCS and presented a cost-consequence
model [8]. The aim is to evaluate whether the Sherlock
Fig. 1 Diagram of heart
(Cardiff University Media
Resources)
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3CG TCS carries a clinical advantage and/or a reduced
cost in comparison to current NHS standard care.
3.1 Company’s submission of clinical effectiveness
evidence
The company identified and submitted 4 relevant studies
[9–12]. None of the submitted studies were peer reviewed
or published in full. Two studies were from the USA, one
from Australia and one from the UK. The company also
identified a study that was pending publication [13], and
subsequently published. Given the paucity of evidence, the
EAC widened the scope to include any previous models of
the technology that included both ECG measurement and
magnetic tracking. This resulted in one presentation being
included [14]. The company also submitted information
from questionnaires that it had sent to selected NHS users
of the Sherlock 3CG TCS.
3.2 Critique of clinical evidence available
3.2.1 Peer reviewed evidence
The only available peer reviewed paper reported a retro-
spective analysis of the first 250 PICC insertions following
introduction of the Sherlock 3CG TCS to an NHS
intensive care unit (ICU) [13]. PICCs were placed by the
Vascular Access Team at the bedside and, following tip
confirmation with the Sherlock 3CG TCS, a portable
X-ray was used to assess placement accuracy. Eleven out
of 250 patients (4 %) were excluded due to difficulties
interpreting the ECG (n = 4), other PICC difficulties
(n = 3), or X-ray difficulties (n = 4). The authors reported
49 out of 239 (21 %) tip placements were not in the correct
position using European guidelines (Pittiruti guideline).
A paper by the same group reported accuracy of blind
bedside PICC placement shortly before the introduction of
the Sherlock 3CG TCS [15]. The EAC has presented the
results of both papers in Table 1, although the studies do
not directly compare identical populations. The malposi-
tion rate using the Sherlock 3CG TCS is significantly
lower than the blind placement (p\ 0.0001) and the
authors conclude that if this definition of tip placement is
acceptable, then the Sherlock 3CG TCS can be used for
tip confirmation without routine chest X-ray confirmation.
3.2.2 Other Evidence
Results from non-peer-reviewed evidence such as
abstracts, posters and presentations are summarised in
Table 2.
The accuracy of the Sherlock 3CG TCS in Johnston
et al. [13] (Table 1) is lower than that reported in five other
studies (Table 2); possibly because ICU patients have less
clear heart rhythm or are recumbent. It is unclear if the
results from this one study are generalisable to other set-
tings (either to other ICU settings or the wider NHS).
Questionnaires completed by six NHS sites using the
Sherlock 3CG TCS highlighted the variation in normal
clinical pathways for tip insertion and confirmation, repo-
sitioning and reinsertion. At the time of submission, the
company reported that nine NHS sites had stopped using
routine chest X-rays for tip confirmation, from a total of 16
NHS sites that have introduced the Sherlock 3CG TCS.
3.2.3 Summary
All studies used the Sherlock 3CG TCS as the interven-
tion; none were comparative. The studies reported the use
of the Sherlock 3CG TCS for tip confirmation, followed
by a chest X-ray to determine if the tip was in the correct
place. There were no comparators giving information on
the blind PICC placement malposition rates in the same
setting. The studies all stop at the point of tip confirmation
and assessment by chest X-ray. It is not known if PICCs
identified as malpositioned had to be adjusted or re-in-
serted, or what the consequences might be. Similarly, the
studies do not give any indication if any patients would
have been identified as having misplaced PICCs without
the chest X-ray, and what the clinical implications might
have been.
Several of the sites from the published abstracts [9–12,
14] report that routine chest X-rays are no longer used to
confirm PICC placement. The sponsors report that nine
NHS sites using Sherlock 3CG TCS have had sufficient
confidence in the device to remove the requirement for
routine chest X-rays to confirm tip location.
3.3 Cost Evidence
Two studies included cost information [9, 10], but con-
tained insufficient information for critical analysis, and had
limited relevance to the decision problem. The EAC did
not find any additional studies that should have been
included. Only two of the six clinical studies identified
report the time taken to insert the PICC and complete tip
confirmation using Sherlock 3CG TCS (without chest
X-ray), and compare it to the time taken by the previous
method. There was no evidence for the effect on staff time,
time to deliver treatment, bed days, clinical outcome or
patient experience.
The company created an economic model with four
branches:
1. Bedside PICC placement with Sherlock 3CG TCS
with X-ray.
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2. Bedside PICC placement with Sherlock 3CG TCS
without X-ray.
3. Blind bedside PICC placement, with X-ray.
4. Fluoroscopy guided placement.
Inputs to the model were based on the studies and NHS
questionnaires submitted as clinical evidence. Staff costs
were derived from the Personal Social Services Research
Unit (PSSRU) [16], and detailed pathway information and
costs for blind bedside PICC placement and fluoroscopy
were obtained from Walker et al. [17, 18].
Using this cost model, the company found that the
Sherlock 3CG TCS without X-ray gave a cost saving of
GBP25.67 per patient compared to blind bedside PICC
insertion, and a cost saving of GBP510.03 per patient
compared to fluoroscopy. All costs are based on 2014
values.
3.4 Critique of Economic Submission
There are uncertainties in the model structure and inputs
due to the lack of data available and the variations in
patient groups and service provision. The company carried
out extensive sensitivity analysis, although the EAC dis-
agreed with some of the key inputs. Important assumptions
and data for the model submitted by the company, along
with the views of the EAC, are listed below.
3.4.1 Time Horizon
The model stops at the point of confirming PICC tip
placement. The EAC considered that a preferable time
horizon would include adverse events, complications, the
time to starting treatment and the clinical consequences.
Unfortunately, there is no evidence available to inform
such a model and the impact and direction of any effect is
unknown.
3.4.2 Nurse Time
The difference in staff time is one of the model’s key
drivers. The two studies used in the company’s model were
from different countries with different health systems,
causing the EAC to consider comparability unlikely. The
values used by the company were:
• 62.49 min for blind PICC insertion with X-ray and the
Sherlock 3CG TCS with X-ray, based on Walker and
Todd [17] bedside placement time.
• 39.5 min for the Sherlock 3CG TCS without X-ray
[9].
3.4.3 Reinsertion Rates and Method
The difference in reinsertion rates and cost of reinsertion is
a key driver when comparing blind bedside PICC insertion
to the Sherlock 3CG TCS. The proportion of accurate
placement the model uses is:
• 96 % for the Sherlock 3CG TCS [10] for trained staff.
This study used a comparison to X-ray to judge
accuracy. Where the normal pathway does not include
a chest X-ray, a malposition will only be detected if it
causes a clinical problem.
• 93.1 % for blind bedside PICC placement [17].
• 100 % for fluoroscopy [17].
The base case of the cost model assumes that all identified
tip malpositions will require replacement, and that all rein-
sertions would be performed using fluoroscopy. Not all
malpositions will require reinsertion procedures, and although
some services may reinsert PICCs using fluoroscopy, others
will use bedside techniques. Because the model includes more
malpositions for blind PICC placement than for the Sherlock
3CG TCS, and fluoroscopy is the most costly option, these
assumptions favour the Sherlock 3CG TCS.
3.4.4 Patient Population
The scope defined by NICE included all adult patients
undergoing PICC insertion. The population included in the
company’s model was adult patients undergoing PICC
insertion who were suitable for ECG tip confirmation using
the Sherlock 3CG TCS. The company assumed 83.5 % of
patients were suitable [9], and did not include costs for
treatment of the remaining 16.5 % by an alternative
Table 1 Number of tips correctly placed using the Sherlock 3CG TCS and prior to its introduction [13, 15]
Definition of adequate tip position Sherlock 3CG TCS
(Johnston 2014 [13])
Blind bedside PICC placement prior to the
Sherlock 3CG TCS (Johnston 2013 [15])
ICU ICU Non-ICU
(n = 239) % and 95 % CI (n = 246) % (n = 233) %
Mid and low SVC/CAJ/high RA (upper 2 cm) 190 79.5 (74–84) 121 49.2 136 58.4
CAJ cavo-atrial junction, CI confidence interval, ICU intensive care unit, PICC peripherally inserted central catheter, RA right atrium, SVC
superior vena cava
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method. This has a low impact on the model where the two
comparative arms have similar costs. Expert advice indi-
cated that the proportion of patients for whom the Sherlock
3CG TCS is suitable was likely to be higher than 83.5 %.
The company’s instructions for use state that use of the
technology is limited (but not contraindicated) in patients
who do not have an identifiable P wave, e.g. those with
atrial fibrillation, tachycardia, etc.
3.4.5 Fluoroscopy
The company’s model finds a large cost saving using the
Sherlock 3CG TCS at the bedside compared to fluo-
roscopy. This is partially due to the high cost attributed to
fluoroscopy—much of the remaining cost saving is due to
the move to bedside placement and would be equally true
of blind PICC bedside placement.
The cost of theatre for fluoroscopy was assumed by the
company to be GBP507.18 [17, 18]. The EAC estimated
this cost to be GBP101 [19].
If standard practice was fluoroscopy, and a new bedside
PICC placement service had to be set up, there would be
costs for nurse training and reorganisation. The model does
not include these initial set up costs.
3.5 EAC Alternative Scenarios
There are unavoidable uncertainties due to the lack of evi-
dence, and the variations in patient groups and service
provision. There are many inputs and scenarios that can
change the model from being cost saving to cost incurring—
the most accurate representation will depend on the service
being examined. The EAC analysis presents an alternative
set of assumptions—there is insufficient evidence to allow
absolute certainty over which is most appropriate.
3.5.1 EAC Changes to Company’s Model
The EAC changes to the company’s base model were:
• Nurse time is equal for blind PICC insertion with
X-ray, the Sherlock 3CG TCS with X-ray and the
Sherlock 3CG TCS without X-ray. The EAC used a
time of 62.49 min [17]. X-rays are costed separately.
• Where the Sherlock 3CG TCS is used without X-ray,
there is an assumption of zero malpositions being
identified within the time frame of the model, since no
other tip confirmation system is used.
• Replacements for PICCs placed at the bedside are by
the same method as the original placement.
• In patients for whom use of the Sherlock 3CG TCS is
not suitable, treatment costs by an alternative method
were included.
• The cost of theatre use for fluoroscopy was changed to
GBP101 [19].
Using these inputs, the EAC found that the Sherlock
3CG TCS without X-ray incurred a cost of GBP9.37 per
patient compared to blind bedside PICC insertion, and gave
a cost saving of GBP106.12 per patient compared to fluo-
roscopy. All costs are based on 2014 values.
3.5.2 EAC Cost Neutral Scenario
The EAC explored a scenario where the use of the Sherlock
3CG TCS is approximately cost neutral when the fol-
lowing assumptions are made (in addition to the previous
EAC changes):
• Nurse time for the Sherlock 3CG TCS is 57.5 min, a
5-min reduction from the original EAC assumption, as
there is no requirement for the nurse to interpret the
X-ray image.
• The cost of X-ray is assumed to be 10 min of
radiologist time (GBP5.67, company’s submission,
based on Walker and Todd [17]) with the addition of
15 min for a Band 2 porter (GBP5.25 [16]) to transport
patient to and from X-ray. This gives total X-ray cost of
GBP10.92.
Using these inputs, the EAC found that the Sherlock
3CG TCS without X-ray was associated with a cost
saving of GBP1.17 per patient compared to blind bedside
PICC insertion, and a cost saving of GBP111.27 per patient
compared to fluoroscopy.
3.5.3 EAC Scenario Based on ICU Data
The EAC also explored a scenario based on ICU data [13,
15], changing the accuracy rates to those in Table 1.
Sherlock 3CG TCS with X-ray was used in the model,
reflecting the local practice at the time of publication [13].
The limitations of this scenario are:
• the data is taken from a single centre and may not be
generalisable.
• the comparison is with historical data from the same
centre.
• the study only includes intermediate outcomes—the
actual number of replacements is not reported.
In this scenario, the Sherlock 3CG TCS with X-ray
confirmation is associated with a cost saving of GBP41.35
per patient compared to blind bedside PICC insertion,
because of the significant reduction in the proportion of
malpositioned catheters that needed to be re-positioned.
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3.6 Impact of Changes
Given current information, use of the Sherlock 3CG TCS
compared to blind PICC insertion using a chest X-ray
appears to hover around cost neutral. Staff time and
accuracy are key drivers in the model, but evidence for
these is sparse and the reality will vary in different situa-
tions. If evidence became available for outcomes after the
initial insertion, such as replacement, complications and
adverse events, the cost implications may change. The
direction of this potential change is not known.
4 NICE Guidance
4.1 Preliminary Guidance
The NICE Medical Technologies Advisory Committee
(MTAC) met in October 2014 and considered evidence from
a range of sources, including the company’s submission, the
EAC report and additional economic modelling, and testi-
mony from clinical experts. The committee made provi-
sional recommendations that went to public consultation.
The Committee considered the overall quality and
quantity of the evidence to be low, but noted that the
general trend of the clinical evidence was in favour of the
Sherlock 3CG TCS, and that the technology seemed
likely to be cost neutral. Some additional analysis was
carried out by the EAC to further test the impact of staff
time on the cost model.
4.2 Consultation Response
During the consultation period, NICE received 14 consul-
tation comments from 7 consultees (3 NHS professionals, 2
manufacturers, the Department of Health, and one EAC
representative). The majority of these comments were
process-related, and considered if the single-technology
assessment methods used by MTEP were appropriate for
medical technologies evaluation. At the final guidance
meeting (January 2015), the Committee considered these
comments with reference to the MTEP’s process and
methods guides [20, 21] and concluded that they should not
impact on the provisional recommendations. Accordingly,
the recommendations did not change substantively as a
result of public consultation.
4.3 Final Recommendations
The NICE Medical Technology Guidance on the Sherlock
3CG TCS for placement of peripherally inserted central
catheters was published on 25 March 2015 as MTG 24 [3].
It contains the following recommendations:
1. The case for adopting the Sherlock 3CG TCS for
placement of peripherally inserted central catheters is
supported by the evidence. The technology usually
avoids the need for a confirmatory chest X-ray in
patients who would otherwise have blind insertion,
minimising the delay before the catheter can be used
for infusion. Using the technology increases staff
confidence during catheter insertion.
2. The Sherlock 3CG TCS should be considered as an
option for placement of peripherally inserted central
catheters in adults. For patients whose electrocardio-
gram does not show a P wave (for example, patients
with atrial fibrillation), a chest X-ray will still be
needed to confirm tip location of the peripherally
inserted central catheter.
3. The cost of using the Sherlock 3CG TCS is similar to
that of blind insertion and subsequent chest X-ray in
adults who need a peripherally inserted central catheter
in a non-intensive care setting. When the Sherlock
3CG TCS is used instead of fluoroscopy, the
estimated cost saving is GBP106 per patient. In an
intensive care setting, where the rate of misplacement
with blind insertion is generally higher, there is an
estimated cost saving of GBP41 per patient per use of
the Sherlock 3CG TCS and a confirmatory chest
X-ray compared with using blind insertion and chest
X-ray. All these cost savings are subject to some
uncertainty and need to be considered in the context of
the clinical benefits.
5 Key Challenges and Learning Points
The wide range of uses for PICCs meant that it was diffi-
cult to identify a typical patient pathway. Clinical expertise
was the key to understanding different pathways and their
implications.
The most widely reported outcome was accuracy of the
PICC placement judged against chest X-ray. This is an
intermediate outcome, rather than the actual clinical or
economic information important to a decision.
Sensitivity analysis and alternative scenarios helped to
understand the range of possible outcomes within the
structure of the model, and to reflect the diverse clinical
realities. Where there is no clinical evidence for the actual
outcomes needed, there can only be limited confidence in
the economic model.
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